HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.

BACKGROUND & AIMS Our aims were to study the virologic, histologic, and clinical outcome in chronic hepatitis B (CHB) patients with hepatitis B surface antigen (HBsAg) seroclearance. METHODS We determined the age of HBsAg seroclearance that is associated with a lower risk for hepatocellular carcinoma (HCC) in 298 CHB patients (median follow-up, 108 months). The following virologic and histologic features were also determined: liver stiffness (n = 229), liver histology, serum HBV DNA levels over time (n = 265), intrahepatic HBV DNA with covalently closed circular DNA (cccDNA) levels, and messenger RNA (mRNA) expression. RESULTS The median age of HBsAg seroclearance was 49.6 years. Seven (2.4%) patients developed HCC. Cumulative risk for HCC was higher in patients with HBsAg seroclearance at ages >or=50 years compared with those with HBsAg seroclearance at ages <50 (P = .004) years. Of these 2 groups of patients, 29.5% and 7.9%, respectively, had significant fibrosis by liver stiffness measurement (P = .001), and 15.4% of patients had mild histologic fibrosis. Intrahepatic total HBV DNA and cccDNA were detected in 100% and 79.3% of patients, respectively. All patients had undetectable surface and precore/pregenomic RNA transcripts. One (9.1%) patient had X mRNA expression. Serum HBV DNA were detectable in 13.4%, 6.1%, and 3.7% of patients within 1 year and 5-10 and >10 years after HBsAg seroclearance, respectively, and 82.1% patients had persistently normal alanine aminotransferase levels. CONCLUSIONS HBV persisted at low replicative and transcriptional levels after HBsAg seroclearance. HBsAg seroclearance at age <50 years was associated with a lower risk for the development of HCC.

[1]  R. Sampliner,et al.  The Liver Histology and Frequency of Clearance of the Hepatitis B Surface Antigen (HBsAg) in Chronic Carriers , 1979, The American journal of the medical sciences.

[2]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[3]  B. McMahon,et al.  The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. , 1985, The Journal of infectious diseases.

[4]  H. Hsu,et al.  Clearance of hepatitis B surface antigen (HBsAg) after surgical resection of hepatocellular carcinoma. , 1987, Journal of hepatology.

[5]  M. Loriot,et al.  Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. , 1990, Annals of internal medicine.

[6]  B. McMahon,et al.  Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. , 1990, Archives of internal medicine.

[7]  C. Chu,et al.  Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study , 1991, Hepatology.

[8]  S. Kaneko,et al.  Clearance of HBsAg in seven patients with chronic hepatitis B , 1992, Hepatology.

[9]  H. Hsu,et al.  Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection , 1992, Hepatology.

[10]  A. Mason,et al.  Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. , 1992, Gastroenterology.

[11]  J. Hoofnagle,et al.  Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B , 1993, Hepatology.

[12]  M. Loriot,et al.  Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. , 1997, Journal of hepatology.

[13]  L. Mimms,et al.  The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia , 1997, Hepatology.

[14]  M. Yu,et al.  Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non‐Asians in Los Angeles County, California , 1997 .

[15]  S. Wirth,et al.  Detection of different viral strains of hepatitis B virus in chronically infected children after seroconversion from HBsAg to anti-HBs indicating viral persistence. , 1997, Journal of hepatology.

[16]  F. Chang,et al.  Sero‐clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis , 1998, Hepatology.

[17]  G. Fattovich,et al.  Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis , 1998, American Journal of Gastroenterology.

[18]  Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis , 1998 .

[19]  I. Mushahwar,et al.  Immunoassay detection of hepatitis B surface antigen mutants , 1999, Journal of medical virology.

[20]  H. Kawasaki,et al.  Occult hepatitis B virus infection in HBs antigen‐negative hepatocellular carcinoma in a Japanese population: Involvement of HBx and p53 , 2000, Journal of medical virology.

[21]  M. Komori,et al.  Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. , 2001, Journal of hepatology.

[22]  C. Bréchot,et al.  Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? , 2001, Hepatology.

[23]  C. Chu,et al.  Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. , 2002, Gastroenterology.

[24]  C. Siu,et al.  HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects , 2004, Hepatology.

[25]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[26]  Y. N. Park,et al.  Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. , 2005, Journal of hepatology.

[27]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[28]  Yoshiyuki Suzuki,et al.  Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. , 2006, The American journal of medicine.

[29]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[30]  M. Yuen,et al.  Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. , 2006, Journal of hepatology.

[31]  V. Alves,et al.  Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic type B hepatitis. Lack of correlation with hepatitis C and D virus superinfection , 1996, Journal of Gastroenterology.

[32]  Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease , 2007, Antiviral therapy.

[33]  Huy A. Nguyen,et al.  Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.